Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DFV1I4
|
|||
| Drug Name |
QBW251
|
|||
| Synonyms |
Icenticaftor; 1334546-77-8; Qbw251; Icenticaftor [INN]; Icenticaftor [USAN]; AMB0BO0WFH; QBW-251; 3-Amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-2-pyridinecarboxamide; 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide; (S)-3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide; 2-Pyridinecarboxamide, 3-amino-6-methoxy-N-((2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-; 2-pyridinecarboxamide, 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-; UNII-AMB0BO0WFH; Icenticaftor [USAN:INN]; SCHEMBL2372751; CHEMBL4650318; GTPL11547; US10117858, Example 5; BDBM297402; DTXSID601336884; WHO 11246; AKOS040759841; compound 33 [PMID: 34028270]; MS-25717; HY-109177; CS-0116371; 3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J40-J44, J47; ICD-9: 490-492, 494-496] | Phase 2 | [1] | |
| Company |
Novartis Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H13F6N3O3
|
|||
| Canonical SMILES |
CC(CNC(=O)C1=C(C=C(C(=N1)OC)C(F)(F)F)N)(C(F)(F)F)O
|
|||
| InChI |
InChI=1S/C12H13F6N3O3/c1-10(23,12(16,17)18)4-20-8(22)7-6(19)3-5(11(13,14)15)9(21-7)24-2/h3,23H,4,19H2,1-2H3,(H,20,22)/t10-/m0/s1
|
|||
| InChIKey |
USHQRIKZLHNPQR-JTQLQIEISA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | cAMP-dependent chloride channel (CFTR) | Target Info | Potentiator | [2] |
| KEGG Pathway | ABC transporters | |||
| cAMP signaling pathway | ||||
| AMPK signaling pathway | ||||
| Gastric acid secretion | ||||
| Pancreatic secretion | ||||
| Bile secretion | ||||
| Vibrio cholerae infection | ||||
| Reactome | ABC-family proteins mediated transport | |||
| WikiPathways | ABC-family proteins mediated transport | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04268823) A Randomized, Subjects and Investigator Blinded, Placebo Controlled Parallel Group Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health. | |||
| REF 2 | Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). J Cyst Fibros. 2021 Mar;20(2):250-256. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.